Europe Facial Injectable Market

• High number of facial injectable procedures is driving the market growth

The cosmetics industry has grown significantly over the last ten years. There has been an increase in the overall number of non-surgical operations, such as wrinkle relaxer and dermal filler injections, due to the rise in aesthetic attractiveness and accessibility of highly complex cosmetic procedures. This advancement can largely be attributed to the advantages of technology, such as short recovery times, reduced infection risks, less blood loss, and decreased overall procedural costs. For instance, according to data from the International Society of Aesthetic Plastic Surgery (ISAPS), more than 10,129,528 cosmetic surgical procedures were performed in 2021. The most common non-surgical procedures in 2021 will be calcium hydroxylapatite (222,785), poly-L-lactic acid (121,087), botulinum toxin, and hyaluronic acid. The market is expected to increase throughout the forecast period due to the large number of facial injectable procedures.

The geriatric population is also steadily growing, which supports the market's expansion. For instance, one in six individuals worldwide will be 60 years of age or older by 2030, predicts the WHO estimate from 2021. By 2050, there will be 1.4 billion persons in this age group, up from 1 billion in 2020. There will be 2.1 billion persons over the age of 60 in the world by 2050. The number of adults 80 and older is projected to treble between 2020 and 2050, reaching 426.0 million.

Growing the geriatric population is projected to support the market's growth over the forecast period because this generation is the primary target for cosmetic operations. Thus, driving the Europe Facial Injectable Market revenue.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Europe Facial Injectable Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Facial Injectable industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Facial Injectable industry to benefit clients and increase the market sector. In recent years, the Facial Injectable industry has offered some of the most significant advantages to medicine. Major players in the Europe Facial Injectable Market, including Allergan Inc (Ireland), Merz Pharma (Germany), Ipsen (France), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Integra Lifesciences (Us), Tei Biosciences, Fibrogen (Finland), and Ethicon (Us), are attempting to increase market demand by investing in research and development operations.

Gavin S. Herbert, a chemist, created the pharmaceutical business Allergan in 1948. It merged with Irish pharmaceutical company Actavis plc in 2015 to form Allergan plc, an American company with Irish headquarters that develops, produces, and sells brand-name drugs and medical devices for the central nervous system, gastroenterology, medical aesthetics, and eye care. Allergan joined AbbVie in 2023, a multinational pharmaceutical corporation with a focus on the development, production, and marketing of branded pharmaceutical, device, biologic, and biosimilar medicines.

The 60+ illnesses that Allergan treats with its more than 30 products range from oncology and immunology to cosmetics and eye care. They produce a range of pharmaceutical goods, including Botox, which has both therapeutic and aesthetic uses. A division of Allergan, Allergan Aesthetics creates, produces, and sells a range of premium brands and goods for the face, body, cosmetic surgery, and skin care.

Founded in Frankfurt, Germany, Merz Pharma is a privately held pharmaceutical firm with affiliates throughout Europe, the US, Canada, Mexico, Brazil, and Asia Pacific. Regional offices are also located in Singapore and North Carolina, USA. The business engages in product discovery, research, and distribution for neurologically induced movement disorders and aesthetic medicine. One of the pioneers in aesthetic medicine, Merz Aesthetics offers a wide range of cutting-edge skin care products. The mission of Merz Therapeutics is to meet the special requirements of those with mobility problems, neurological illnesses, and other medical issues.

With its tetesept and Merz Spezial brands, Merz Consumer Care sells items for health, wellness, and beauty. The business has devoted more than 110 years to creating technologies that enhance patients' quality of life and health. The three businesses Merz Aesthetics, Merz Therapeutics, and Merz Consumer Care make up the multinational, family-owned corporation Merz.